Neridronate inhibits angiogenesis in vitro and in vivo

被引：30
作者：
Ribatti, D.
Nico, B.
Mangieri, D.
Maruotti, N.
Longo, V.
Vacca, A.
Cantatore, F. P.
机构：
[1] Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy
[2] Univ Foggia, Sch Med, Dept Rheumatol, Foggia, Italy
[3] Univ Bari, Sch Med, Dept Biomed Sci & Clin Oncol, Bari, Italy
来源：
CLINICAL RHEUMATOLOGY | 2007年 / 26卷 / 07期
关键词：
anti-angiogenesis; bisphosphonate; chorioallantoic membrane; endothelial cells; neridronate;
D O I：
10.1007/s10067-006-0455-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The effects of the amino-bisphosphonate neridronate on endothelial cell functions involved in angiogenesis, namely, proliferation and morphogenesis on Matrigel were tested in vitro, whereas its effects on angiogenesis were studied in vivo, by using the chick embryo chorioallantoic membrane (CAM) assay. In vitro, neridronate inhibited endothelial cell proliferation in a dose-dependent fashion, peaking at 30 mu M. At the same concentration, neridronate inhibited fibroblast growth factor-2 (FGF-2)-induced capillary-like tube formation in the morphogenesis assay on Matrigel. In vivo, when tested in the CAM assay, neridronate again displayed the capability to inhibit FGF-2-induced angiogenesis. Overall, these results suggest that anti-angiogenesis by neridronate could be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer.
引用
收藏
页码：1094 / 1098
页数：5
相关论文
共 19 条
[1]   Developments in the therapeutic applications of bisphosphonates [J].
Brown, DL ;
Robbins, R .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (07) :651-660
[2]   Alternative bisphosphonate targets and mechanisms of action [J].
Bukowski, JF ;
Dascher, CC ;
Das, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 328 (03) :746-750
[3]   Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival [J].
Croucher, PI ;
De Raeve, H ;
Perry, MJ ;
Hijzen, A ;
Shipman, CM ;
Lippitt, J ;
Green, J ;
Van Marck, E ;
Van Camp, B ;
Vanderkerken, K .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (03) :482-492
[4]   Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients [J].
Ferretti, G ;
Fabi, A ;
Carlini, P ;
Papaldo, P ;
Fei, PC ;
Di Cosimo, S ;
Salesi, N ;
Giannarelli, D ;
Alimonti, A ;
Di Cocco, B ;
D'Agosto, G ;
Bordignon, V ;
Trento, E ;
Cognetti, F .
ONCOLOGY, 2005, 69 (01) :35-43
[5]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[6]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[7]  
Fournier P, 2002, CANCER RES, V62, P6538
[8]   An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis [J].
Giraudo, E ;
Inoue, M ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (05) :623-633
[9]   Antitumor effects of bisphosphonates [J].
Green, JR .
CANCER, 2003, 97 (03) :840-847
[10]   A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis [J].
Hamma-Kourbali, Y ;
Di Benedetto, M ;
Ledoux, D ;
Oudar, O ;
Leroux, Y ;
Lecouvey, M ;
Kraemer, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (03) :816-823
12